Patrick J Heron bought $69k of ARQT
director at Arcutis Biotherapeutics, Inc.. 5,040 shares at an average of $13.66, traded May 21, 2025, filed May 23, 2025.
Score components
- +15RoleDirector
- +8Trade size$69k at market
- +6Relative to holdingsHoldings up 29%
- +4Price context20% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying4 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-014415, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 21, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +2,520 | $13.66 | $34k | 20,014 | May 23, 2025 |
| May 22, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +2,520 | $13.65 | $34k | 22,534 | May 23, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 6Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $136k 10,139 shares | -8% | |
| 33Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $35k 2,646 shares | +11% | |
| 32Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $30k 2,268 shares | +10% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $25k 1,800 shares | -1% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Larry Todd Edwards See Remarks | $105k 7,451 shares | -4% | |
| 33Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $34k 2,520 shares | +17% | |
| 44Moderate | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $119k 8,674 shares | +138% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.